VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,423,311 | +12.5% | 27,919 | +10.2% | 0.03% | +21.4% |
| Q2 2023 | $1,265,679 | -17.0% | 25,344 | -37.7% | 0.03% | -9.7% |
| Q1 2023 | $1,524,574 | -30.8% | 40,677 | -11.4% | 0.03% | -39.2% |
| Q4 2022 | $2,202,583 | +345.0% | 45,935 | +102.1% | 0.05% | +292.3% |
| Q2 2022 | $495,000 | -32.5% | 22,733 | -25.1% | 0.01% | -23.5% |
| Q1 2022 | $733,000 | +3.8% | 30,369 | +2.3% | 0.02% | 0.0% |
| Q4 2021 | $706,000 | -6.2% | 29,680 | 0.0% | 0.02% | -19.0% |
| Q3 2021 | $753,000 | -31.9% | 29,680 | -39.6% | 0.02% | -41.7% |
| Q2 2021 | $1,106,000 | +1.9% | 49,121 | -10.6% | 0.04% | -12.2% |
| Q1 2021 | $1,085,000 | +39.8% | 54,931 | +88.0% | 0.04% | +41.4% |
| Q4 2020 | $776,000 | +39.1% | 29,212 | +65.6% | 0.03% | -23.7% |
| Q2 2020 | $558,000 | – | 17,637 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |